HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. - Wikidata - wikimedia - TriplyDB

HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.

HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.

http://www.wikidata.org/entity/Q33763000

about

Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings Integrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early Treatment How Stigma Surrounding the Use of HIV Preexposure Prophylaxis Undermines Prevention and Pleasure: A Call to Destigmatize "Truvada Whores"Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review Prodrugs of phosphonates and phosphates: crossing the membrane barrier Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study Applying a PrEP Continuum of Care for Men Who Have Sex With Men in Atlanta, Georgia Facilitators of adherence to the study pill in the FEM-PrEP clinical trial Antiretroviral Drug Activity in Macaques Infected during Pre-Exposure Prophylaxis Has a Transient Effect on Cell-Associated SHIV DNA Reservoirs ARV-based HIV prevention for women - where we are in 2014.The Influence of Pastors' Ideologies of Homosexuality on HIV Prevention in the Black Church.Effects of tenofovir on cytokines and nucleotidases in HIV-1 target cells and the mucosal tissue environment in the female reproductive tract.Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa.Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial Intimacy, condom use, and pre-exposure prophylaxis (PReP) acceptability among men who have sex with men (MSM) in primary partnerships: a comment on Gamarel and Golub.Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.Preparing for the Rollout of Pre-Exposure Prophylaxis (PrEP): A Vignette Survey to Identify Intended Sexual Behaviors among Women in Kenya and South Africa if Using PrEP Pharmacokinetics of antiretrovirals in mucosal tissue Rethinking HIV prevention to prepare for oral PrEP implementation for young African women The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention Seasonal PrEP for partners of migrant miners in southern Mozambique: a highly focused PrEP intervention.Motivations for Reducing Other HIV Risk-Reduction Practices if Taking Pre-Exposure Prophylaxis: Findings from a Qualitative Study Among Women in Kenya and South Africa.Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda Sexual Behavior, Risk Compensation, and HIV Prevention Strategies Among Participants in the San Francisco PrEP Demonstration Project: A Qualitative Analysis of Counseling Notes Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women.Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.Nondaily preexposure prophylaxis for HIV prevention.Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports.Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection.Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.The preexposure prophylaxis revolution; from clinical trials to programmatic implementation.A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.The Potential of Pre-Exposure Prophylaxis for Women in Violent Relationships Periconception HIV Risk Behavior Among Men and Women Reporting HIV-Serodiscordant Partners in KwaZulu-Natal, South Africa.

P2860

Q26753097-ECD4254C-2784-4E08-A0B4-63EBD940927D Q26778085-9C424294-D191-45E6-AF58-2D20E81F2829 Q26798250-215FC9A3-BBD0-43C2-94E8-6ED31986952F Q26849762-498DAB2A-47D1-4DA3-9AE1-03AF27D3357B Q27005712-3587D07A-B090-4A98-9478-23B33133B953 Q27023352-3F0A85F2-7E7A-402E-9057-2032AB0B84BD Q27300707-15242B07-A789-46AC-B2B7-2CA2DE8E471C Q28088473-474045BE-8AC9-4AF7-A339-C20785ACE0C5 Q28546083-6EB406D2-9362-4D2A-A97F-764330B21F9A Q28553127-09A0AAB2-AD84-4126-9DEE-2504FA465B62 Q34180729-3C3234DA-A933-4142-84F1-0766266BD898 Q34522941-EF04D45B-6F67-4A55-BA39-2A0E127A326B Q34596532-6328CD95-A9EE-476C-9629-28BAE7797E95 Q35007321-381B5C8C-F6B5-48FB-842C-78AD01B0DA59 Q35163040-F94DA091-D1BC-4C0B-86BC-E77CB07E1E4B Q35163705-918CC517-CAD4-492C-9431-3CA3C137FB0F Q35473551-B7AE14E6-E4D3-4AD4-B858-77C193A3CEA2 Q35657813-AF327BE5-8ED1-40CF-8D2B-095D1DCB08B2 Q35838594-06B77113-5BB1-4D0F-9895-DF1B38BA4FF7 Q35875710-456707A0-007E-4727-9E0B-AF542D8C49ED Q35875723-E075C2C5-8383-402A-ADDF-A60F1A051EE8 Q35875733-728547F0-7448-4DDC-88B7-C166CA91A98F Q36006842-5EE0B279-7D27-4CAC-A3CE-40808AD5BC48 Q36110276-485D5237-C2B5-40AE-AC2D-1FAEC4471F05 Q36118829-65675BDD-4B2B-41F8-BA1D-1CE5A628E9CF Q36149022-E2E3F763-95EE-44BE-8295-932252DC1EB0 Q36251754-DB586ED2-A09E-44E4-88D1-5F95B048A71B Q36290753-F84BF8A4-20FB-492D-85C8-97DCEB3F9D39 Q36406923-528EC8AB-4FE3-454E-B494-E391012C84D2 Q36443803-3D6A761F-4B7D-4066-A01F-7FA69732C788 Q36629910-79379CA6-6921-4821-B1DB-1143F255AA55 Q36669377-8C79582E-DCD3-49D5-A7D4-E5483C542BF1 Q36739989-ECDA5B6B-4CBB-43BF-827A-1EB2136A1237 Q36816564-11DE1B7B-174B-4C69-8540-924987982029 Q36933427-88C80A0B-88E4-40F9-881A-2FED3312E265 Q36934918-44CE64BA-D082-424C-9691-30F11C64E764 Q36988613-4C4AF749-B5FF-4565-8887-169BE647B91C Q37003034-72337D16-8E48-4981-879E-B650E59C1D69 Q37019969-737F426F-4A88-4C6E-B159-51733DD1643B Q37050396-5818154E-AE03-4A52-BB67-D5C864396A2D

P2860

HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.

http://www.wikidata.org/entity/Q33763000

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

HIV protective efficacy and co ...... al of PrEP for HIV prevention.

@ast

HIV protective efficacy and co ...... al of PrEP for HIV prevention.

@en

type

label

HIV protective efficacy and co ...... al of PrEP for HIV prevention.

@ast

HIV protective efficacy and co ...... al of PrEP for HIV prevention.

@en

prefLabel

HIV protective efficacy and co ...... al of PrEP for HIV prevention.

@ast

HIV protective efficacy and co ...... al of PrEP for HIV prevention.

@en

P1433

Q33763000-2688EA12-54A6-4A44-B326-BE15437D451A

P1476

Q33763000-81E34AFD-3B14-4C05-B7D2-DE053859C2F8

P2093

Q33763000-1872CCD0-127A-4685-A12D-914DF859B436

Q33763000-1E5E4865-A5C9-4684-B33C-F415548C573C

Q33763000-56287467-2C51-43AC-8886-CA7D81A47E62

Q33763000-A836CDC6-3C92-4FD6-8B01-4836EE620814

Q33763000-ABCE8E9C-7705-4726-A79B-874003779D59

Q33763000-C3DF276B-C52A-4834-AAB8-AE19A27DAC01

Q33763000-D7F47838-644C-44A6-A123-3DC5300B42C0

Q33763000-DFA76AD7-3A51-4B31-B950-D4E97C4720BB

P2860

Q33763000-08414FA0-AEF4-462A-9130-4ABD43C792F0

Q33763000-0C030229-CA3F-4212-9D9F-036F9D4B9C1A

Q33763000-167CD919-5476-4F7F-9CD9-04CC7EFED831

Q33763000-26FCBC77-9E50-4278-B2FE-C881A441249B

Q33763000-28E2C735-758D-4DEC-9EB1-7F42E8EFEFF8

Q33763000-2F789EAA-976F-42F8-8EE2-734BD0D9AB83

Q33763000-43FB220C-2E13-47F5-852B-761E6D988309

Q33763000-490C5B94-681A-4833-B9D0-120784C2B8DE

Q33763000-4A7482F9-37FA-4C44-8C5E-5255A71C4CA2

Q33763000-4C8FDF99-D073-4C9D-B2C6-62449FB0DCEA

P304

Q33763000-AFD685E1-1220-4EC6-B3A0-2D678DE95442

P31

Q33763000-0732697A-E49D-490C-835D-75C25ED5939D

P356

Q33763000-A0690DF1-6617-4C90-A212-7CAE3C44EF32

P407

Q33763000-EB043B61-7F5B-48D9-AFD0-013097DD04D3

P433

Q33763000-B61794B8-6384-4E46-B10E-38D3CC1A33B3

P478

Q33763000-B26ED4C9-BF63-4347-98A2-062234BF5C08

P50

Q33763000-2E043357-2071-4CF8-9076-866B5D2BA762

Q33763000-57003379-E0EC-48D0-84FE-7CCBF9F0F325

Q33763000-D9E21D90-B0B1-41F2-B4A7-8CD45E2178FD

P577

Q33763000-F31438B1-9578-4574-A21B-BF94D2B5660C

P5875

Q33763000-72174897-FF67-4484-9D26-CBC76F6AD6EF

P698

Q33763000-1A9F0036-CA99-4EF8-9868-F3BD1CB941CF

P921

Q33763000-9843D50C-36B6-4758-A2AE-E0EBFA30F21E

P932

Q33763000-9AC7A422-4D1C-4E3B-A9CE-203C1388E037

P356

QAI.0000000000000172

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

HIV protective efficacy and co ...... al of PrEP for HIV prevention.

@en

P2093

Andrew Mujugira

http://www.w3.org/2001/XMLSchema#string

Craig Hendrix

http://www.w3.org/2001/XMLSchema#string

Jared M Baeten

http://www.w3.org/2001/XMLSchema#string

Jessica E Haberer

http://www.w3.org/2001/XMLSchema#string

Justin Brantley

http://www.w3.org/2001/XMLSchema#string

Namandjé N Bumpus

http://www.w3.org/2001/XMLSchema#string

Nelly Mugo

http://www.w3.org/2001/XMLSchema#string

Patrick Ndase

http://www.w3.org/2001/XMLSchema#string

P2860

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial

The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies

Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa

Preexposure prophylaxis for HIV infection among African women

Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana

Improved Horvitz-Thompson Estimation of Model Parameters from Two-phase Stratified Samples: Applications in Epidemiology

A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.

Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study.

P304

340-348

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0000000000000172

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

Deborah Donnell

David R Bangsberg

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262015191

http://www.w3.org/2001/XMLSchema#string

P698

24784763

http://www.w3.org/2001/XMLSchema#string

P921

prevention of HIV/AIDS

P932

4059553

http://www.w3.org/2001/XMLSchema#string